GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

G-Pen

Company
Xeris Pharmaceuticals
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
6 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

6 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for G-Pen and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05708859

    Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

    Not yet reported Matthew J. Budoff 120 participants Est. completion 2026-05 1 site
    Other conditions: Type II Diabetes, Atherosclerosis
    View official trial listing →
  • Recruiting NCT NCT06406114

    Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

    Not yet reported Massachusetts General Hospital 300 participants Est. completion 2028-12-31 6 sites
    Other conditions: Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity, Antibiotic Allergy, Beta Lactam Adverse Reaction, Drug-Induced Anaphylaxis, Cephalosporin Reaction
    View official trial listing →
  • Recruiting NCT NCT06630585

    GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes

    Not yet reported University of Bern 42 participants Est. completion 2026-06 3 sites
    Other conditions: Type 1 Diabetes (T1D)
    View official trial listing →
  • Recruiting NCT NCT06651177

    Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

    Not yet reported T. John Winhusen, PhD 310 participants Est. completion 2027-10-31 9 sites
    Substance use disorder
    View official trial listing →
  • Recruiting NCT NCT06820281

    Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes

    Not yet reported Victor Chang Cardiac Research Institute 44 participants Est. completion 2027-12-31 1 site
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Recruiting NCT NCT07326111

    A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese

    Not yet reported University of Bonn 198 participants Est. completion 2029-12 2 sites
    Other conditions: Polycystic Ovary Syndrome (PCOS), Obesity & Overweight
    View official trial listing →
  • Completed NCT NCT00574249

    Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment

    Not yet reported Abbott 730 participants 131 sites
    Other conditions: Chronic Plaque Psoriasis
    View official trial listing →
  • Terminated NCT NCT01334606

    Evaluation of a 4mmx32G Pen Needle for Injection of Basal Insulin Doses Above 40 Units

    Not yet reported Becton, Dickinson and Company 21 participants Est. completion 2011-06 3 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01476475

    Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

    Not yet reported Sanofi 323 participants Est. completion 2012-12 70 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01517412

    Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin

    Not yet reported Sanofi 451 participants Est. completion 2013-05 82 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01768559

    Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

    Not yet reported Sanofi 894 participants Est. completion 2014-12 199 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01818336

    Evaluation of Skin Testing Reagents for Penicillin Allergy

    Not yet reported AllerQuest LLC 481 participants Est. completion 2013-06 13 sites
    Other conditions: History of IgE Dependent Reaction to a Penicillin Product
    View official trial listing →
  • Completed NCT NCT01972152

    Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia

    Not yet reported Xeris Pharmaceuticals 30 participants Est. completion 2014-02 1 site Stand-alone
    Other conditions: Hypoglycemia
    View official trial listing →
  • Completed NCT NCT02081014

    Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes

    Not yet reported Xeris Pharmaceuticals 13 participants Est. completion 2014-11 1 site Stand-alone
    Other conditions: Hypoglycemia
    View official trial listing →
  • Terminated NCT NCT02099240

    Patients Response to Early Switch To Oral:Osteomyelitis Study

    Not yet reported Julio Ramirez 11 participants Est. completion 2018-11-07 1 site
    Other conditions: Osteomyelitis
    View official trial listing →
  • Completed NCT NCT02411578

    Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia

    Not yet reported Jaeb Center for Health Research 26 participants Est. completion 2016-05 5 sites Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT02423980

    G-Pen™ for Hypoglycemia Rescue in T1D Patients

    Not yet reported Xeris Pharmaceuticals 7 participants Est. completion 2015-06 1 site Stand-alone
    Other conditions: Hypoglycemia
    View official trial listing →
  • Completed NCT NCT02656069

    Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

    Not yet reported Xeris Pharmaceuticals 80 participants Est. completion 2017-09-25 7 sites
    Other conditions: Hypoglycemia, Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT02660242

    The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes

    Not yet reported Jaeb Center for Health Research 16 participants Est. completion 2017-02-15 2 sites Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT03091673

    Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients

    Not yet reported Xeris Pharmaceuticals 31 participants Est. completion 2017-09-27 7 sites Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT03439072

    G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes

    Not yet reported Xeris Pharmaceuticals 81 participants Est. completion 2018-05-03 6 sites
    Other conditions: Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
    View official trial listing →
  • Status unknown NCT NCT03668834

    Comparing Recipient Site Preparation Using Dermabrasion, Dermaroller and Liquid Nitrogen Induced Blister in Non Cultured Epidermal Cell Suspension in Stable Vitiligo

    Not yet reported Post Graduate Institute of Medical Education and Research, Chandigarh 36 participants Est. completion 2019-06-30 1 site
    Other conditions: Vitiligo
    View official trial listing →
  • Completed NCT NCT03738865

    G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes

    Not yet reported Xeris Pharmaceuticals 132 participants Est. completion 2019-04-02 7 sites Stand-alone
    Other conditions: Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
    View official trial listing →
  • Status unknown NCT NCT04591457

    The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus

    Not yet reported Indonesia University 120 participants Est. completion 2021-08 1 site
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Status unknown NCT NCT04828239

    Acupuncture Versus Laser Acupuncture for Carpal Tunnel Syndrome

    Not yet reported Kuang Tien General Hospital 150 participants Est. completion 2022-06-20 1 site
    Other conditions: Carpal Tunnel Syndrome
    View official trial listing →
  • Completed NCT NCT05564039

    A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

    Not yet reported Eli Lilly and Company 282 participants Est. completion 2024-08-12 38 sites Added to GLP-1
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05691712

    A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

    Not yet reported Eli Lilly and Company 257 participants Est. completion 2024-07-01 25 sites
    Other conditions: Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
    View official trial listing →
  • Active, not recruiting NCT NCT05693545

    GOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD Trial

    Not yet reported Children's Hospital Medical Center, Cincinnati 1004 participants Est. completion 2027-09-30 1 site
    Other conditions: Rheumatic Heart Disease
    View official trial listing →
  • Completed NCT NCT05810597

    A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices

    Not yet reported Eli Lilly and Company 65 participants Est. completion 2023-07-17 3 sites
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT05963022

    A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)

    Not yet reported Eli Lilly and Company 206 participants Est. completion 2024-10-09 28 sites
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07367711

    The Influence of Chemotherapy on Position Sense

    KU Leuven 145 participants Est. completion 2027-11 1 site
    Other conditions: CIPN - Chemotherapy-Induced Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07738276

    Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity

    Not yet reported Shahid Beheshti University of Medical Sciences 60 participants Est. completion 2027-12-22
    Heart failure Other conditions: Obesity & Overweight, Tirzepatide
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.